Boyages J, Taylor R, Chua B, Ung O, Bilous M, Salisbury E, Wilcken N
New South Wales Breast Cancer Institute, Westmead, New South Wales, Australia.
Br J Surg. 2006 May;93(5):564-71. doi: 10.1002/bjs.5207.
This study compared the application of the St Gallen 2001 classification with a risk index developed at the New South Wales Breast Cancer Institute (BCI Index) for women with node-negative breast cancer treated without adjuvant systemic therapy.
The BCI risk categories were constructed by identifying combinations of prognostic indicators that produced homogeneous low-, intermediate- and high-risk groups using the same variables as in the St Gallen classification.
The BCI low-risk category consisted of women aged 35 years or more with a grade 1 oestrogen receptor (ER)-positive tumour 20 mm or less in diameter, or with a grade 2 ER-positive tumour of 15 mm or less. This category constituted 40.1 per cent of patients, with a 10-year distant relapse-free survival (DRFS) rate of 97.2 per cent. The BCI intermediate-risk category included women aged 35 years or more with a grade 2 ER-positive tumour of diameter 16-20 mm, or a grade 1 or 2 ER-negative tumour measuring 15 mm or less, and comprised 12.1 per cent of the women, with a 10-year DRFS rate of 88 per cent. The high-risk category comprised 47.7 per cent of women, with a 10-year DRFS rate of 68.4 per cent.
If confirmed in other data sets, the BCI Index may be used to identify women at low risk of distant relapse (2.8 per cent at 10 years) who are unlikely to benefit from adjuvant systemic therapy, and women at intermediate risk of distant relapse (12 per cent at 10 years) in whom the benefit of adjuvant systemic therapy is small.
本研究比较了圣加仑2001年分类法与新南威尔士州乳腺癌研究所制定的风险指数(BCI指数)在未接受辅助全身治疗的淋巴结阴性乳腺癌女性中的应用。
BCI风险类别是通过识别预后指标的组合构建而成的,这些组合使用与圣加仑分类法相同的变量产生了同质的低、中、高风险组。
BCI低风险类别包括年龄35岁及以上、肿瘤直径20毫米及以下的1级雌激素受体(ER)阳性肿瘤患者,或直径15毫米及以下的2级ER阳性肿瘤患者。该类别占患者的40.1%,10年远处无复发生存率(DRFS)为97.2%。BCI中风险类别包括年龄35岁及以上、直径16 - 20毫米的2级ER阳性肿瘤患者,或直径15毫米及以下的1级或2级ER阴性肿瘤患者,占女性患者的12.1%,10年DRFS率为88%。高风险类别占女性患者的47.7%,10年DRFS率为68.4%。
如果在其他数据集中得到证实,BCI指数可用于识别远处复发风险低(10年时为2.8%)、不太可能从辅助全身治疗中获益的女性,以及远处复发风险中等(10年时为12%)、辅助全身治疗获益较小的女性。